JP2019504105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504105A5 JP2019504105A5 JP2018540862A JP2018540862A JP2019504105A5 JP 2019504105 A5 JP2019504105 A5 JP 2019504105A5 JP 2018540862 A JP2018540862 A JP 2018540862A JP 2018540862 A JP2018540862 A JP 2018540862A JP 2019504105 A5 JP2019504105 A5 JP 2019504105A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tumor
- composition
- administration
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022192529A JP7597452B2 (ja) | 2016-02-05 | 2022-12-01 | 中枢神経系のがんの治療のための組換えｔ細胞の投与 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662292152P | 2016-02-05 | 2016-02-05 | |
| US62/292,152 | 2016-02-05 | ||
| US201662309348P | 2016-03-16 | 2016-03-16 | |
| US62/309,348 | 2016-03-16 | ||
| PCT/US2017/016711 WO2017136829A1 (en) | 2016-02-05 | 2017-02-06 | Administration of engineered t cells for treatment of cancers in the central nervous system |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022192529A Division JP7597452B2 (ja) | 2016-02-05 | 2022-12-01 | 中枢神経系のがんの治療のための組換えｔ細胞の投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504105A JP2019504105A (ja) | 2019-02-14 |
| JP2019504105A5 true JP2019504105A5 (2) | 2020-03-19 |
| JP7189019B2 JP7189019B2 (ja) | 2022-12-13 |
Family
ID=59496551
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540862A Active JP7189019B2 (ja) | 2016-02-05 | 2017-02-06 | 中枢神経系の癌の治療のための操作されたｔ細胞の投与 |
| JP2022192529A Active JP7597452B2 (ja) | 2016-02-05 | 2022-12-01 | 中枢神経系のがんの治療のための組換えｔ細胞の投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022192529A Active JP7597452B2 (ja) | 2016-02-05 | 2022-12-01 | 中枢神経系のがんの治療のための組換えｔ細胞の投与 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20170224733A1 (2) |
| EP (2) | EP3411393B1 (2) |
| JP (2) | JP7189019B2 (2) |
| KR (1) | KR20180105709A (2) |
| CN (1) | CN108779160A (2) |
| AU (2) | AU2017213661B2 (2) |
| BR (1) | BR112018015836A2 (2) |
| CA (1) | CA3013773A1 (2) |
| DK (1) | DK3411393T3 (2) |
| ES (1) | ES2879700T3 (2) |
| IL (2) | IL287889B2 (2) |
| MX (1) | MX2023006304A (2) |
| RU (1) | RU2757308C2 (2) |
| WO (1) | WO2017136829A1 (2) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| US10611837B2 (en) | 2014-04-10 | 2020-04-07 | Seattle Children's Hospital | Transgene genetic tags and methods of use |
| AU2016306209B2 (en) | 2015-08-07 | 2023-07-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific CAR T-cells for solid tumor targeting |
| IL287889B2 (en) | 2016-02-05 | 2024-03-01 | Hope City | Administration of engineered t cells for treatment of cancers in the central nervous system |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| US11408005B2 (en) | 2016-12-12 | 2022-08-09 | Seattle Children's Hospital | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| CN109971725B (zh) * | 2017-12-28 | 2024-02-02 | 上海细胞治疗研究院 | 抗体修饰的嵌合抗原受体修饰t细胞及其用途 |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| AU2019225174B2 (en) | 2018-02-23 | 2025-11-20 | Endocyte, Inc. | Sequencing method for CAR T cell therapy |
| EA202091984A1 (ru) * | 2018-03-14 | 2021-02-18 | Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) | Направленная дзетакинами т-клеточная иммунотерапия, нацеленная на рецептор il-13 альфа 2 |
| EP3765041A4 (en) | 2018-03-14 | 2021-12-22 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | IL-13 CHIMERIC RECEPTOR ALPHA 2 (IL13RA2) ANTIGEN RECEPTOR FOR T-CELL T-CELL IMMUNOTHERAPY |
| US20190284553A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| US12590133B2 (en) | 2018-06-01 | 2026-03-31 | The Board Of Trustees Of The Leland Stanford Junior University | IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof |
| CN115551882A (zh) * | 2020-01-31 | 2022-12-30 | 希望之城公司 | 用于治疗IL13Rα2阳性恶性病的靶向性嵌合抗原受体修饰的T细胞 |
| JP2023520410A (ja) * | 2020-03-31 | 2023-05-17 | フレッド ハッチンソン キャンサー センター | Ｃｄ３３を標的にするキメラ抗原受容体 |
| CN115348973A (zh) | 2020-03-31 | 2022-11-15 | 弗莱德哈钦森癌症中心 | 靶向cd33的嵌合抗原受体 |
| CN113646433B (zh) * | 2020-07-16 | 2022-10-11 | 苏州博腾生物制药有限公司 | 靶向抗TNF-α抗体的组合物和方法 |
| JP2023550148A (ja) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法 |
| CN117242090A (zh) * | 2021-03-30 | 2023-12-15 | 希望之城公司 | CAR T细胞疗法和IFNγ |
| WO2025235801A1 (en) | 2024-05-08 | 2025-11-13 | City Of Hope | Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7514537B2 (en) * | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| US11278594B2 (en) | 2001-04-30 | 2022-03-22 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| SI2856876T1 (en) * | 2007-03-30 | 2018-04-30 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| EP2331566B1 (en) * | 2008-08-26 | 2015-10-07 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| WO2011059836A2 (en) * | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| WO2012066495A2 (en) * | 2010-11-17 | 2012-05-24 | Ben Gurion University Of The Negev Research And Development Authority | T-cell therapy to neurodegenerative diseases |
| EP2885428B1 (en) * | 2012-08-17 | 2017-05-03 | Memorial Sloan-Kettering Cancer Center | Gene expression profile associated with prostate cancer |
| IL238323B2 (en) * | 2012-10-30 | 2023-11-01 | Esperance Pharmaceuticals Inc | Antibody/drug conjugates and methods of use |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| CN113307880B (zh) * | 2014-01-13 | 2025-07-04 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| CA2945388A1 (en) * | 2014-04-23 | 2015-10-29 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) for use in therapy and methods for making the same |
| AU2016306209B2 (en) * | 2015-08-07 | 2023-07-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific CAR T-cells for solid tumor targeting |
| CN105131126B (zh) * | 2015-10-10 | 2019-02-01 | 北京康爱瑞浩细胞技术有限公司 | 用于治疗恶性肿瘤的嵌合抗原受体及其制备方法与应用 |
| IL302560B2 (en) | 2015-10-13 | 2025-08-01 | Hope City | Chimeric antigen receptors containing a chlorotoxin domain |
| KR20180083874A (ko) * | 2015-11-04 | 2018-07-23 | 사울 제이. 프라이스맨 | Her2를 표적화하는 키메라 항원 수용체 |
| IL287889B2 (en) | 2016-02-05 | 2024-03-01 | Hope City | Administration of engineered t cells for treatment of cancers in the central nervous system |
| CN115551882A (zh) | 2020-01-31 | 2022-12-30 | 希望之城公司 | 用于治疗IL13Rα2阳性恶性病的靶向性嵌合抗原受体修饰的T细胞 |
| WO2021183755A1 (en) | 2020-03-11 | 2021-09-16 | City Of Hope | Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatment |
| CA3175123A1 (en) | 2020-03-12 | 2021-09-16 | City Of Hope | Targeted chimeric antigen receptor modified t cells for treatment of il13r.alpha.2 positive malignancies |
| AU2021342126A1 (en) | 2020-09-10 | 2023-05-18 | City Of Hope | Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer |
-
2017
- 2017-02-06 IL IL287889A patent/IL287889B2/en unknown
- 2017-02-06 WO PCT/US2017/016711 patent/WO2017136829A1/en not_active Ceased
- 2017-02-06 EP EP17748349.2A patent/EP3411393B1/en active Active
- 2017-02-06 AU AU2017213661A patent/AU2017213661B2/en active Active
- 2017-02-06 DK DK17748349.2T patent/DK3411393T3/da active
- 2017-02-06 RU RU2018130752A patent/RU2757308C2/ru active
- 2017-02-06 CN CN201780017442.9A patent/CN108779160A/zh active Pending
- 2017-02-06 CA CA3013773A patent/CA3013773A1/en active Pending
- 2017-02-06 EP EP21166981.7A patent/EP3912993A1/en not_active Withdrawn
- 2017-02-06 US US15/425,773 patent/US20170224733A1/en not_active Abandoned
- 2017-02-06 ES ES17748349T patent/ES2879700T3/es active Active
- 2017-02-06 JP JP2018540862A patent/JP7189019B2/ja active Active
- 2017-02-06 KR KR1020187025196A patent/KR20180105709A/ko not_active Ceased
- 2017-02-06 BR BR112018015836-4A patent/BR112018015836A2/en active Search and Examination
-
2018
- 2018-08-01 IL IL260930A patent/IL260930B/en unknown
- 2018-08-03 MX MX2023006304A patent/MX2023006304A/es unknown
-
2020
- 2020-09-18 US US17/025,723 patent/US12472233B2/en active Active
-
2022
- 2022-09-02 AU AU2022224866A patent/AU2022224866A1/en not_active Abandoned
- 2022-12-01 JP JP2022192529A patent/JP7597452B2/ja active Active
-
2025
- 2025-10-07 US US19/351,506 patent/US20260027181A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504105A5 (2) | ||
| Pol et al. | Trial watch: oncolytic viruses for cancer therapy | |
| MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| BR112018074192A8 (pt) | Método para tratamento de um sujeito, método para produzir uma composição celular, composição de células, composição de vacina e kit | |
| TW202428301A (zh) | 治療性rna | |
| RU2017126610A (ru) | Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47 | |
| JP2018502120A5 (2) | ||
| JP2020510624A5 (2) | ||
| EA201490911A1 (ru) | Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина | |
| JP2016528162A5 (2) | ||
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| Shou et al. | Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy | |
| WO2021182573A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| PH12015502260A1 (en) | C. novyi for the treatment of solid tumors in humans | |
| EP4100030A1 (en) | Oncolytic virus compositions and methods for the treatment of cancer | |
| JP2017537927A5 (2) | ||
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| Sai et al. | Basic and translational research on carbon-ion radiobiology | |
| Xia et al. | Nanobody engineered and photosensitiser loaded bacterial outer membrane vesicles potentiate antitumour immunity and immunotherapy | |
| WO2022238963A3 (en) | Genetically engineered immune cells targeting cd70 for use in treating solid tumors | |
| He et al. | Role of tumor-associated macrophages in breast cancer immunotherapy | |
| Sun et al. | Combining immunotherapy with radiotherapy for glioblastoma: recent advances and challenges | |
| Marcu | Improving Therapeutic Ratio in Head and Neck Cancer with Adjuvant and Cisplatin‐Based Treatments | |
| WO2022020648A9 (en) | Inhibitors of the artemin pathway for treatment of cancer | |
| Gutova et al. | Intranasal delivery of therapeutic neural stem cells to target intracerebral glioma |